Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Chicago
With
National Cancer Institute (NCI)
OBJECTIVES:
* Determine the feasibility of performing reverse transcriptase-polymerase chain reaction (RT-PCR) for five different tumor antigen genes using lymph node samples or peripheral blood from patients with melanoma.
* Determine the ability of PCR-positive lymph nodes or peripheral blood to predict relapse of disease in these patients.
* Determine the correlation of positive PCR results from peripheral blood with disease stage.
OUTLINE: Lymph node biopsies or peripheral blood are obtained from patients. These specimens are examined by nested reverse transcriptase-polymerase chain reaction (RT-PCR) and analyzed for various tumor antigens.
Patients may choose to be told the results of this testing, but the results do not influence or change the planned therapy. Brief counseling is required to discuss the results and their potential implications.
Patients are followed for at least 2 years.
PROJECTED ACCRUAL: A total of 30 patients for the lymph node portion and 80 patients (20 per stage of disease) for the peripheral blood portion will be accrued for this study within 3 years.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
DISEASE CHARACTERISTICS:
Clinically proven melanoma with indication to perform sentinel lymph node biopsy or elective lymph node dissection OR
Histologically proven or diagnosis highly suspicious for melanoma
PATIENT CHARACTERISTICS:
Age:
Any age
Performance status:
Not specified
Life expectancy:
Not specified
Hematopoietic:
Platelet count greater than 50,000/mm\^3
Hemoglobin greater than 7 g/dL
Hepatic:
PT less than 15 sec
PTT less than 30 sec
Renal:
Not specified
Other:
No psychiatric illness that precludes compliance
No other concurrent malignancy
PRIOR CONCURRENT THERAPY:
Biologic therapy
Not specified
Chemotherapy
Not specified
Endocrine therapy
Not specified
Radiotherapy
Not specified
Surgery
Not specified
Clareo Health | Detection of Melanoma Markers in Lymph Nodes or Peripheral Blood of Patients With Melanoma